Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404539 | 0.90 | NPSR1 (0.46) | MAPTNPSR1GAAMEN1KMT2A | |
| SCHEMBL25258057 | 0.90 | NPSR1 (0.46) | MAPTNPSR1GAAMEN1KMT2A | |
| SCHEMBL29405659 | 0.85 | NPSR1 (0.41) | MAPTNPSR1GAAMEN1KMT2A | |
| SCHEMBL25256150 | 0.85 | NPSR1 (0.41) | MAPTNPSR1GAAMEN1KMT2A | |
| SCHEMBL29405164 | 0.79 | MAPK1 (0.53) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25256531 | 0.79 | MAPK1 (0.53) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29405099 | 0.78 | LMNA (0.58) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL25301864 | 0.78 | LMNA (0.58) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL25258035 | 0.77 | CYP11B2 (0.43) | MAPTNPSR1GAAMEN1KMT2A | |
| SCHEMBL29402177 | 0.77 | CYP11B2 (0.43) | MAPTNPSR1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | LMITO THERAPEUTICS INC. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240034719-A1 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | LMITO THERAPEUTICS INC. (KR) | 2024-02-01 | — | — | US | disclosed |
| EP-4212530-A1 | IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | Lmito Therapeutics Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-115956071-A | Imidazoquinoline or benzindazolone compounds and intermediates for their preparation | LMITO药业株式会社 | 2023-04-11 | — | — | CN | disclosed |
| WO-2022039460-A1 | IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | 주식회사 엘마이토테라퓨틱스 | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034719-A1 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | NQO1, NFE2L2, KEAP1 | MAPT 217/4885NPSR1 4198/4885GAA 1904/4885 |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | NQO1, CBR1, NFE2L2 | MAPT 1433/4885NPSR1 2859/4885GAA 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.